CN Patent

CN120813354A — 用于向患有肝损伤的患者施用帕妥索汀的组合物和方法

Assigned to Crinetics Pharmaceuticals Inc · Expires 2025-10-17 · 1y expired

What this patent protects

提供了用于向患有肝损伤的患者施用帕妥索汀或其药学上可接受的盐的组合物和方法。

USPTO Abstract

提供了用于向患有肝损伤的患者施用帕妥索汀或其药学上可接受的盐的组合物和方法。

Drugs covered by this patent

amifampridine-phosphate (AMIFAMPRIDINE PHOSPHATE)

Patent Metadata

Patent number: CN120813354A
Jurisdiction: CN
Classification: —
Expires: 2025-10-17
Drug substance claim: No
Drug product claim: No
Assignee: Crinetics Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.